Tag Archives: Meridian Bioscience

February 2023—SD Biosensor and SJL Partners LLC, both based in South Korea, have completed the transaction to acquire Meridian Bioscience. Meridian will continue to operate as an independent entity, under new ownership, headquartered in Cincinnati. Meridian offers immunoassay and molecular raw materials for human and veterinarian diagnostics testing, and it plans to add service capabilities for lyophilized bead and lateral flow test manufacturing.

Feb. 24, 2020—Meridian Bioscience launched High-Specificity Pfu HS Mix, a high-fidelity PCR master mix containing an aptamer to create a reversible, temperature-dependent hot-start and Pfu buffer, tailored for low GC bias amplification.

September 2019—Meridian Bioscience has acquired Quebec City-–based GenePOC, a provider of molecular diagnostic instruments and assays.

Sept. 14, 2016—Donna Mayne, the microbiology, serology, and molecular laboratory manager at Sacred Heart Health System in Pensacola, Fla., outlines the clinical benefits of using molecular technology to detect Mycoplasma pneumoniae in a free program provided by Meridian Bioscience. Watch. In a separate presentation, Vicki Chalker, PhD, head of the respiratory and vaccine-preventable bacteria reference unit of Public Health England’s ...

Meridian Bioscience has received FDA clearance for its Mycoplasma pneumoniae molecular diagnostic test on the Illumigene platform. By amplifying the specific DNA for the detection of M. pneumoniae, the test provides a definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner.

Meridian Bioscience’s Illumigene group A Streptococcus and group B Streptococcus tests have been recategorized under CLIA as moderate complexity. The new categorization of these tests allows the Illumigene platform to be available to all moderate-complexity labs in U.S. hospitals and clinics, allowing them to offer an accurate, rapid, simple molecular test for each of these pathogens.

Meridian Bioscience has completed beta trials for two new Illumigene molecular amplification tests specifically designed to detect the DNA of Chlamydia trachoma-tis and Neisseria gonorrhoeae, respectively, from swab and urine specimens.